Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41% on placebo, with significant improvements in joint and skin symptoms continuing through 24 weeks. The drug demonstrated a favorable safety profile with no new safety concerns. These results highlight ICOTYDE's potential as a new oral treatment option for psoriatic arthritis, addressing both joint and skin disease.
Johnson & Johnson holds a market cap of $664.95 billion and offers a dividend yield of 1.94% as of Nov 07, 2026 22:21 WIB. The stock price on Pluang is USD 276.22, up 1.43% for the day, with a trading volume of 8,859,117 shares. Despite a slight majority of sell orders at 53%, the typical investor holds JNJ shares for about 130 days, indicating steady interest in the company.
Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...
As of late 2026, the average 1-year certificate of deposit (CD) rate stands at 1.76%, below the Federal Reserve's target range. Some investors are considering blue-chip dividend stocks like Microsoft, Johnson & Johnson, and Coca-Cola, which offer pot...
The FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO, a dual-targeted therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based chemotherapy and anti...
Five dividend-paying stocks in sectors like pharmaceuticals, software, food, and utilities are highlighted for their strong dividend coverage and resilience during economic slowdowns. Johnson & Johnson, IBM, Pfizer, General Mills, and Dominion Energy...
Johnson & Johnson announced the FDA's accelerated approval of RYBREVANT FASPRO, a dual-targeted subcutaneous therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and anti-PD-(L)1 anti...
